With a very well established infrastructure and processes, Mendelics has consolidated a quality management system focused on meeting international quality standards, audited on a yearly basis by nationally and internationally recognized entities. Mendelics is the first and largest Latin American laboratory specialized in genomic diagnosis tests for rare diseases and cancer through the Next Generation Sequencing (NGS) technique.
Mission
To make genomic diagnosis fast, accurate, and accessible to everyone who needs it.
Vision
To be one of the main world references in genomic diagnosis and interpretation. To provide technology and process transfers for central labs
Duplicate Mendelics' efficiency and processes in your labs
Large Scale Projects
Mendelics has the ability to process and facilitate large scale projects in and out of Latin America
Expanded Newborn Screening
Mendelics has proficiency in non-invasive newborn screening for over 340 genes
Therapeutic Areas:
Cardiology
Dermatology
Endocrinology
Medical Genetics
Hematology
gastroenterology
Opthalmology
Otorhinolaryngology
Nephrology
Neurology
Oncology
Women's Health
About Global Life Sciences Alliance (GLSA)
GLSA’s Global Network of solutions providers incorporates a variety of CROs and specialty vendors to support the specific needs of your clinical trial. Our network includes full-service CROs, biometrics, site selection, patient recruitment and retention, clinical supply chain management, and more. GLSA pre-qualifies all members of our network so you can be comfortable working with quality service providers.
We connect Sponsors with the CRO that hasthe right experience, culture, and capabilities to execute their research protocol.We leverage our extensive experience and harness our key relationships to work for CROs. We can fill any gaps you need to support your client’s trials. GLSA takes the guesswork out of vendor selection with our industry experts and experience.
What are your challenges?Contact GLSA to learn more about how we can help you accelerate your speed to market.
